RP-12146

N/A

Report date: 2024/02/28 15:50:12
NME

Base Information

Drug NameRP-12146
Drug Alias NameRP-12146
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1Poly (ADP-Ribose) Polymerase 2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaEuropePoland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRhizen Pharmaceuticals Sa
China Registration ClassN/A

Develop Information

Active CompaniesRhizen Pharmaceuticals Sa
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A